CL2009000870A1 - Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros. - Google Patents

Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros.

Info

Publication number
CL2009000870A1
CL2009000870A1 CL2009000870A CL2009000870A CL2009000870A1 CL 2009000870 A1 CL2009000870 A1 CL 2009000870A1 CL 2009000870 A CL2009000870 A CL 2009000870A CL 2009000870 A CL2009000870 A CL 2009000870A CL 2009000870 A1 CL2009000870 A1 CL 2009000870A1
Authority
CL
Chile
Prior art keywords
disorder
disease
fatty acid
acid amide
painful
Prior art date
Application number
CL2009000870A
Other languages
English (en)
Spanish (es)
Inventor
Louis Grenier
Tao Liu
Mark L Behnke
Alfredo C Castro
Catherine A Evans
Michael J Grogan
Daniel A Snyder
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000870(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of CL2009000870A1 publication Critical patent/CL2009000870A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
CL2009000870A 2008-04-09 2009-04-09 Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros. CL2009000870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4368608P 2008-04-09 2008-04-09

Publications (1)

Publication Number Publication Date
CL2009000870A1 true CL2009000870A1 (es) 2010-06-25

Family

ID=40912141

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000870A CL2009000870A1 (es) 2008-04-09 2009-04-09 Compuestos derivados de acidos p-1,3,4-oxadiazolil-2-il-fenilboronicos, inhibidores de amida hidrolasa de acido graso (faah); composicion farmaceutica, utiles para tratar una afeccion, enfermedad o trastorno doloroso, inflamatorio, inmunologico, entre otros.

Country Status (12)

Country Link
US (2) US8957049B2 (enExample)
EP (1) EP2282742A1 (enExample)
JP (1) JP5637982B2 (enExample)
CN (1) CN102046179B (enExample)
AR (1) AR072249A1 (enExample)
AU (1) AU2009233711B2 (enExample)
CA (1) CA2721060A1 (enExample)
CL (1) CL2009000870A1 (enExample)
IL (1) IL208536A0 (enExample)
PE (1) PE20091838A1 (enExample)
TW (1) TW201000107A (enExample)
WO (1) WO2009126691A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
CN102030770B (zh) * 2009-09-25 2012-10-31 北京大学 一种芳香硼酸酯化合物的制备方法
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
CA2789950C (en) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP2012232924A (ja) * 2011-04-28 2012-11-29 Tosoh Corp 新規なナフチルボロン酸化合物及びその製造法
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
CN103889987B (zh) * 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
JP6105594B2 (ja) 2011-09-30 2017-03-29 エンドゥ ファーマシューティカルズ，インコーポレイティド 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
ES2647486T3 (es) 2011-12-22 2017-12-21 Gilead Sciences, Inc. Pirazolo[1,5-a]pirimidinas como agentes antivirales
EA027855B1 (ru) 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
MX2015006715A (es) 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
EP3134418A4 (en) * 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US9828351B2 (en) 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
HRP20191327T1 (hr) 2015-06-03 2019-11-01 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
CN106800569B (zh) * 2016-12-12 2019-04-16 上海中医药大学附属龙华医院 Atg类似物及其制备方法和应用
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018090717A1 (zh) * 2016-11-16 2018-05-24 上海中医药大学附属龙华医院 Atg类似物及其制备方法和应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
CN109180712B (zh) * 2018-08-08 2020-12-25 南京医科大学 一类2-茨醇的芳基硼酸酯衍生物及其应用
CN109096043B (zh) * 2018-08-24 2021-03-12 盐城师范学院 一种2,5-二溴碘苯的合成方法
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
WO2021222637A1 (en) * 2020-04-30 2021-11-04 United States Government As Represented By The Department Of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP3910102A1 (en) 2020-05-12 2021-11-17 Glatfelter Gernsbach GmbH Non-woven fabric containing a disinfecting agent and method for producing the same
WO2022052958A1 (en) 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN112147273B (zh) * 2020-11-02 2022-08-16 北京市理化分析测试中心 一种检测油品中微量酸的方法
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
KR102567789B1 (ko) * 2021-06-08 2023-08-17 한국원자력의학원 신규한 벤조사이아졸 유도체 및 붕소 중성자 포획 요법에 있어서의 이의 용도
MX2023014819A (es) 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
KR102668048B1 (ko) * 2022-08-02 2024-05-22 한국원자력의학원 신규한 벤조사이아졸 유도체 및 이의 용도
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
WO2024254704A1 (en) * 2023-06-15 2024-12-19 The Governors Of The University Of Alberta Hemiboronic heterocyclic compounds and uses thereof

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1268808A (en) * 1985-07-23 1990-05-08 Alan G. Macdiarmid High capacity polyaniline electrodes
CH671400A5 (enExample) * 1986-12-17 1989-08-31 Nii Prikladnych
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3807862A1 (de) * 1988-03-10 1989-09-21 Merck Patent Gmbh Smektische fluessigkristallphase
US5273680A (en) 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5339163A (en) * 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) * 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE59108963D1 (de) 1990-02-01 1998-05-20 Merck Patent Gmbh Verfahren zur Umsetzung von fluorierten Aromaten mit Elektrophilen
DE4014488A1 (de) 1990-05-07 1991-11-14 Merck Patent Gmbh Dioxaborinane und fluessigkristallines medium
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
EP0501268B1 (de) * 1991-02-25 1996-06-12 F. Hoffmann-La Roche Ag Flüssigkristalline Verbindungen mit endständigem 1-Alkinylrest
HUT65823A (en) 1991-04-30 1994-07-28 Procter & Gamble Liquid detergents with an aryl boronic acid and process for using thereof
GB2258232B (en) 1991-07-31 1995-03-15 Merck Patent Gmbh Alkoxymethylene fluoroterphenyls and liquid crystalline medium
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
FR2688783A1 (fr) 1992-03-23 1993-09-24 Rhone Poulenc Chimie Nouveaux borates d'onium ou de complexe organometallique amorceurs cationiques de polymerisation.
FR2688790B1 (fr) * 1992-03-23 1994-05-13 Rhone Poulenc Chimie Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adhesifs.
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
PL167141B1 (pl) 1992-05-12 1995-07-31 Wojskowa Akad Tech Sposób otrzymywania związków ciekłokrystalicznych zawierających pierścień 1,3-dioksa- -2-boranu
JP3255965B2 (ja) 1992-05-26 2002-02-12 昭和シェル石油株式会社 反強誘電性液晶化合物
DE4220065A1 (de) 1992-06-19 1993-12-23 Merck Patent Gmbh Verfahren zur Herstellung von Pyrimidin-Derivaten
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9220189D0 (en) * 1992-09-24 1992-11-04 Central Research Lab Ltd Dioxane derivatives
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
GB9220750D0 (en) * 1992-10-02 1992-11-18 Merck Patent Gmbh Liquid crystalline material forming ananisotropic
DE4236103A1 (de) * 1992-10-26 1994-04-28 Hoechst Ag Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten
US5334144A (en) * 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5576220A (en) * 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
FR2702485B1 (fr) 1993-03-10 1995-04-14 Rhone Poulenc Chimie Compositions à base de polyorganosiloxanes réticulables par voie cationique et leur utilisation dans le domaine de l'antiadhérence papier, de la protection des fibres optiques et des circuits imprimés.
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5417885A (en) * 1993-08-03 1995-05-23 Showa Shell Sekiyu Kabushiki Kaisha Antiferroelectric liquid crystal compound
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
JPH07145174A (ja) 1993-11-22 1995-06-06 Takeda Chem Ind Ltd ジオキサボリナン系化合物、それらの製造方法、該化合物を含む液晶組成物および該組成物を用いた液晶光変調装置
JPH07165717A (ja) 1993-12-16 1995-06-27 Sumitomo Chem Co Ltd 複素環化合物およびその製造法
JPH07206715A (ja) 1994-01-21 1995-08-08 Sumitomo Chem Co Ltd 複素環化合物の製造法
DE19502178A1 (de) 1994-01-27 1995-08-03 Hoechst Ag Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen
WO1995024176A1 (en) * 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) * 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
JP3702426B2 (ja) 1994-08-03 2005-10-05 関東化学株式会社 トリフルオロメチルベンゼン誘導体および液晶組成物
FR2724660B1 (fr) 1994-09-16 1997-01-31 Rhone Poulenc Chimie Amorceurs de reticulation, par voie cationique, de polymeres a groupements organofonctionnels, compositions a base de polyorganosiloxanes reticulables et contenant ces amorceurs et application desdites compositions en antiadherence
JPH0892137A (ja) 1994-09-26 1996-04-09 Sumitomo Chem Co Ltd 芳香族エステル化合物、その製造法および用途
FR2727416A1 (fr) 1994-11-24 1996-05-31 Rhone Poulenc Chimie Nouveaux amorceurs cationiques thermoactivables, de polymerisation et/ou de reticulation et compositions monomeres et/ou polymeres fonctionnels les mettant en oeuvre
DE4445224B4 (de) 1994-12-17 2014-03-27 Merck Patent Gmbh Benzolderivate
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
JP3783246B2 (ja) 1995-07-18 2006-06-07 大日本インキ化学工業株式会社 ｐ−テルフェニル誘導体
EP0755918B1 (de) * 1995-07-28 2000-09-06 Rolic AG Photovernetzbare flüssigkristalline 1,2-Phenylen-Derivate
EP0846670A4 (en) 1995-08-09 1999-01-13 Chisso Corp CYCLOHEXANE DERIVATIVES AND LIQUID CRYSTAL COMPOSITIONS
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
FR2745288B1 (fr) 1996-02-27 1998-04-17 Adir Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9605334D0 (en) 1996-03-13 1996-05-15 British Nuclear Fuels Plc Biodecontamination reactor
ZA974582B (en) 1996-06-03 1998-11-26 American Cyanamid Co Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds
US5998673A (en) 1996-06-03 1999-12-07 American Cyanamid Company 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
DK0811593T3 (da) 1996-06-03 2002-09-02 Basf Ag 1,4-diaryl-2-flour-2-buten som insektcider og acaricider
US5849958A (en) 1997-03-17 1998-12-15 American Cyanamid Company 1,4,diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
US5892131A (en) * 1997-05-29 1999-04-06 American Cyanamid Company Process for the preparation of pesticidal fluoroolefin compounds
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH1025261A (ja) 1996-07-09 1998-01-27 Chisso Corp フェノール誘導体の製造方法
RU2200730C2 (ru) * 1996-07-31 2003-03-20 Шионоги Энд Ко., Лтд. Пара-терфенильные соединения, способ их получения (варианты) и фармацевтическая композиция (варианты)
FR2752582B1 (fr) * 1996-08-21 2003-06-13 Rhone Poulenc Chimie Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adherents
JP3899557B2 (ja) 1996-08-21 2007-03-28 大日本インキ化学工業株式会社 フルオロビフェニル誘導体
JP4526605B2 (ja) * 1996-08-28 2010-08-18 チッソ株式会社 ラテラルハロゲン置換基を有する４環化合物および液晶組成物
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
FR2757530A1 (fr) 1996-12-24 1998-06-26 Rhodia Chimie Sa Utilisation pour la stereophotolithographie - d'une composition liquide photoreticulable par voie cationique comprenant un photoamorceur du type sels d'onium ou de complexes organometalliques
FR2757870B1 (fr) * 1996-12-30 1999-03-26 Rhodia Chimie Sa Utilisation de compositions silicones reticulables par voie cationique sous uv et d'un photoamorceur du type borate d'onium, pour le revetements de joints plats, notamment de joints de culasse
FR2758329B1 (fr) 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
FR2758560B1 (fr) 1997-01-20 2000-02-04 Adir Nouveaux derives d'acides aminophenylboronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
WO1998035924A1 (en) 1997-02-13 1998-08-20 Chisso Corporation Liquid-crystalline compounds having bicyclo[1.1.1]pentane structure, liquid-crystal composition, and liquid-crystal display element
DE19710614A1 (de) 1997-03-14 1998-09-17 Hoechst Ag (1,2,4)-Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6075014A (en) * 1997-06-13 2000-06-13 Northwestern University Inhibitors of β-lactamases and uses therefor
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
DE19909761A1 (de) 1998-04-17 1999-10-21 Merck Patent Gmbh Benzofuran- und Benzodifuran-Derivate
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2000001463A (ja) 1998-06-12 2000-01-07 Dainippon Ink & Chem Inc ４−シアノベンゼン誘導体の製造方法
GB9814450D0 (en) 1998-07-04 1998-09-02 Sharp Kk Novel compounds
GB2339778A (en) 1998-07-17 2000-02-09 Secr Defence Terphenyl Liquid Crystals
WO2000020466A1 (de) 1998-10-01 2000-04-13 Targor Gmbh Katalysatorsystem
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
DE19858594A1 (de) 1998-12-18 2000-06-21 Merck Patent Gmbh Verfahren zur Herstellung von Cyanbenzolboronsäuren
WO2000037476A1 (de) * 1998-12-19 2000-06-29 Basell Polyolefine Gmbh Verfahren zur herstellung von mono- oder di-organo-boranen
EP1147214B1 (en) * 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
JP2003509507A (ja) 1999-09-21 2003-03-11 キネティック リミテッド 液晶化合物
US6309406B1 (en) * 1999-11-24 2001-10-30 Hamit-Darwin-Fresh, Inc. Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening
NZ519183A (en) * 1999-12-03 2005-02-25 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
FR2805273B1 (fr) * 2000-02-18 2006-08-11 Rhodia Chimie Sa Traitement de surface de materiau plastique avec une composition a fonctions reactives polymerisable et/ou reticulable
DE10009714A1 (de) 2000-03-01 2001-09-06 Targor Gmbh Verfahren zur Herstellung von Mono- oder Di-organo-boranen
GB2362882A (en) 2000-06-02 2001-12-05 Sharp Kk Liquid crystalline optionally laterally fluorinated terphenyl with chiral 3,4-di[(un)saturated-alkoxy]butoxy or 1,4-di[(un)saturated-alkoxy]but-2-oxy terminus
AU2001287399A1 (en) 2000-08-16 2002-02-25 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
CA2420178A1 (en) * 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
US6927216B2 (en) * 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
EP1332214B1 (en) * 2000-10-05 2009-11-18 Millenium Pharmaceuticals, Inc. 32144, a human fatty acid amide hydrolase and uses thereof
GB0100110D0 (en) 2001-01-04 2001-02-14 Univ Leeds Modulation of calcium channel activity
WO2002057273A1 (en) * 2001-01-20 2002-07-25 Trigen Limited Serine protease inhibitors comprising a hydrogen-bond acceptor
JP4721027B2 (ja) 2001-03-29 2011-07-13 Ｄｉｃ株式会社 フェニルピリミジン誘導体の製造方法
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6617125B2 (en) * 2001-06-29 2003-09-09 Perkinelmer Life Sciences, Inc. Compositions for enhanced catalyzed reporter deposition
US6858592B2 (en) * 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
DE60205824T2 (de) * 2001-07-09 2006-05-18 Merck Patent Gmbh Thienothiophenderivate
US7217701B2 (en) * 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
CA2462348A1 (en) * 2001-10-12 2003-04-24 Dow Global Technologies Inc. Metal complex compositions and their use as catalysts to produce polydienes
ATE360054T1 (de) * 2001-11-07 2007-05-15 Merck Patent Gmbh Flüssigkristalline verbindung, flüssigkristallines medium und flüssigkristallanzeige
GB0126844D0 (en) * 2001-11-08 2002-01-02 Qinetiq Ltd Novel compounds
EP2769715A3 (en) 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
WO2003050201A1 (fr) * 2001-12-12 2003-06-19 Tokuyama Corporation Matieres electroluminescentes organiques
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
WO2003064484A1 (en) 2002-01-28 2003-08-07 Dow Global Technologies Inc. Metal complex compositions based on cobalt and their use as polymerization catalyst for olefins and dienes
DE10206759A1 (de) * 2002-02-19 2003-08-28 Dragoco Gerberding Co Ag Synergistische Mischungen von 1,2-Alkandiolen
DE10211597A1 (de) 2002-03-15 2003-10-02 Merck Patent Gmbh Verfahren zur Herstellung von Ringverbindungen
AU2003223930A1 (en) * 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
KR100693367B1 (ko) * 2002-06-27 2007-03-12 아스텔라스세이야쿠 가부시키가이샤 아미노알콜 유도체
EP1388538B1 (en) 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US20040115475A1 (en) * 2002-08-14 2004-06-17 Matsushita Electric Industrial Co., Ltd. Aromatic methylidene compound, methylstyrul compound for producing the same, production electroluminescent element
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形
DE10353656A1 (de) * 2002-11-27 2004-06-09 Merck Patent Gmbh Tetrahydropyran-Derivate
US6924269B2 (en) * 2002-12-04 2005-08-02 Vdf Futureceuticals, Inc. Enzyme inhibitors and methods therefor
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
US7456169B2 (en) * 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
JP2004292766A (ja) * 2003-03-28 2004-10-21 Tokuyama Corp 有機エレクトロルミネッセンス素子材料
DE10325438A1 (de) * 2003-05-21 2004-12-09 Bayer Cropscience Ag Difluormethylbenzanilide
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
JP2007505950A (ja) 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
CN1829521B (zh) 2003-06-16 2011-01-26 安纳考尔医药公司 耐水解的含硼治疗剂和使用方法
DE10337497A1 (de) * 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate
US20070293542A1 (en) 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
WO2005041904A2 (en) 2003-10-31 2005-05-12 Fulcrum Pharmaceuticals, Inc. Inhibitors of coronavirus protease and methods of use thereof
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
US20070010559A1 (en) * 2003-11-25 2007-01-11 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP4491666B2 (ja) 2003-12-02 2010-06-30 東ソー株式会社 フルオレン骨格を有するアリールアミン誘導体の製造方法とその合成中間体
GB2410745B (en) 2004-02-06 2007-07-25 Merck Patent Gmbh Cholestanyl derivatives
BRPI0507629A (pt) * 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
DE102004041532A1 (de) 2004-08-27 2006-03-02 Bayer Cropscience Ag Biphenylthiazolcarboxamide
DE102004041530A1 (de) * 2004-08-27 2006-03-02 Bayer Cropscience Ag Biphenylthiazolcarboxamide
US20100286211A1 (en) * 2004-10-08 2010-11-11 Biswajit Das Oxazolidinone derivatives as antimicrobials
EP1812451A4 (en) 2004-11-01 2009-10-21 Nuada Llc COMPOUNDS AND METHODS OF USE THEREOF
WO2006050054A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
AU2005304318A1 (en) 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
DE102005023834A1 (de) * 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituierte[(Phenylethanoyl)amino]benzamide
US7425281B2 (en) * 2004-12-02 2008-09-16 Displaytech, Inc. Liquid crystal compositions comprising an organogermanium compound and methods for using the same
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7767657B2 (en) * 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2006091799A2 (en) 2005-02-22 2006-08-31 Sumation Co. Ltd. High bandgap arylene polymers
US7589066B2 (en) 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
GB2424881B (en) 2005-04-07 2010-11-24 Merck Patent Gmbh Halophenyl derivatives of bisalkylfluorene
JP4792796B2 (ja) 2005-04-08 2011-10-12 東ソー株式会社 ２，３−ジハロビフェニレン誘導体、その前駆化合物及び製造方法
EP1879860A2 (en) 2005-05-10 2008-01-23 Microbia Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
TW200740752A (en) 2005-05-13 2007-11-01 Microbia Inc 4-Biarylyl-1-phenylazetidin-2-ones
EP1726581A1 (en) 2005-05-25 2006-11-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthesis of novel monomers containing the Trifluorovinylidene-group and the Cyanato-group and polymers thereof
AU2006257670A1 (en) 2005-06-14 2006-12-21 Merck Frosst Canada Ltd Reversible inhibitors of monoamine oxidase A and B
KR100659088B1 (ko) * 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
TW200740823A (en) * 2005-08-01 2007-11-01 Ihara Chemical Ind Co Oxadiazole-substituted Sym-triindole derivative and organic el element employing the same
DE102005037925A1 (de) 2005-08-11 2007-02-15 Merck Patent Gmbh Hydro-cyclopenta[a]naphthaline
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US7999137B2 (en) 2005-09-13 2011-08-16 Bayer Cropscience Ag Pesticide bi-phenyl-amidine derivatives
DE602006011363D1 (de) * 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
CA2630806C (en) 2005-12-02 2015-01-06 Sachem, Inc. Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography process
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
GB0602046D0 (en) * 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
RU2642628C2 (ru) * 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
DE102007009944B4 (de) 2006-03-15 2016-04-28 Merck Patent Gmbh Flüssigkristallines Medium und seine Verwendung
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US20090170845A1 (en) 2006-04-13 2009-07-02 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
JP5145753B2 (ja) 2006-04-20 2013-02-20 Ｊｎｃ株式会社 フルオロイソプロピル基を側鎖として有する化合物およびこれを用いた液晶組成物
BRPI0713010A2 (pt) * 2006-06-12 2012-10-09 Anacor Pharmaceuticals Inc compostos para o tratamento de doença periodontal
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
RU2008151762A (ru) 2006-07-27 2010-06-27 Си Ви Терапьютикс, Инк. (Us) Adlh-2 ингибиторы для лечения аддикции
US8034940B2 (en) * 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
EP2052055B1 (de) 2006-08-16 2011-07-06 Merck Patent GmbH Cyclohexen-verbindungen für flüssigkristalline mischungen
ATE476489T1 (de) * 2006-09-13 2010-08-15 Merck Patent Gmbh Fluorphenyl-verbindungen für flüssigkristalline mischungen
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
US7846514B2 (en) 2007-01-24 2010-12-07 Chisso Corporation Liquid crystal compound, liquid crystal composition and, liquid crystal display device
KR101455428B1 (ko) 2007-02-28 2014-10-27 제이엔씨 석유 화학 주식회사 Ｃｆ2ｏ 결합기를 갖는 5 고리 액정 화합물, 액정 조성물 및 액정 표시 소자
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009011904A1 (en) 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2009136646A1 (ja) 2008-05-08 2009-11-12 住友化学株式会社 不飽和有機化合物の製造方法
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine

Also Published As

Publication number Publication date
EP2282742A1 (en) 2011-02-16
TW201000107A (en) 2010-01-01
IL208536A0 (en) 2010-12-30
JP5637982B2 (ja) 2014-12-10
CA2721060A1 (en) 2009-10-15
PE20091838A1 (es) 2009-12-18
AU2009233711A1 (en) 2009-10-15
CN102046179B (zh) 2015-01-14
AR072249A1 (es) 2010-08-18
US20110172186A1 (en) 2011-07-14
AU2009233711B2 (en) 2015-02-12
US20150368278A1 (en) 2015-12-24
US8957049B2 (en) 2015-02-17
WO2009126691A1 (en) 2009-10-15
JP2011516564A (ja) 2011-05-26
CN102046179A (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
PH12012500765A1 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
EA201001554A1 (ru) Ингибиторы модуляторов воспаления: производные олеанолевой кислоты, гомологированные с-17
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
MX2009004233A (es) Compuestos de biaril eter urea.
CL2009001066A1 (es) Compuestos derivados del acido ciclopentano carboxilico sustituido; inhibidores del receptor lpa edg2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, metabolicas, renales, pulmonares, oncologicas, inmunologicas y alergias, entre otras.
CL2008002417A1 (es) Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria
UY33832A (es) Inhibidores de la faah.
AR048712A1 (es) Empleo de amidas de acidos alquilcarboxilicos como favorecedores de la penetracion
UY32062A (es) Inhibidores de beta-secretasa
WO2008024139A3 (en) Inhibitors of fatty acid amide hydrolase
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
CR11629A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA- DESATURASA.
CO6362005A2 (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyetica y su uso para tratar enfermedades mediadas por prostaglandina d2
CL2008003181A1 (es) Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
MX2012006490A (es) Inhibidores azociclicos de hidrolasa de amidas de acidos grasos.
WO2008021625A3 (en) Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
BR112012019120A2 (pt) forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
EA200702072A1 (ru) Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение
EP2417115A4 (en) FATTY ACID AMIDE HYDROLASE INHIBITORS
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
AR072917A1 (es) Composiciones para el tratamiento de la rosacea